2.64 USD
+0.04 (+1.54%)
2.64 USD
0 (0%)
Taking everything into account, HCAT scores 2 out of 10 in our fundamental rating. HCAT was compared to 35 industry peers in the Health Care Technology industry. HCAT has a bad profitability rating. Also its financial health evaluation is rather negative. HCAT has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
HCAT had positive earnings in the past year.
HCAT had a negative operating cash flow in the past year.
HCAT had negative earnings in each of the past 5 years.
In the past 5 years HCAT reported 4 times negative operating cash flow.
1.2 Ratios
HCAT has a Return On Assets (-18.33%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -32.42%, HCAT is in line with its industry, outperforming 54.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.33% | ||
| ROE | -32.42% | ||
| ROIC | N/A |
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 47.49%, HCAT is not doing good in the industry: 68.57% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of HCAT has declined.
HCAT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
2. Health
2.1 Basic Checks
HCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HCAT has more shares outstanding
The number of shares outstanding for HCAT has been increased compared to 5 years ago.
HCAT has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.17, we must say that HCAT is in the distress zone and has some risk of bankruptcy.
HCAT has a worse Altman-Z score (-2.17) than 65.71% of its industry peers.
HCAT has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
HCAT has a worse Debt to Equity ratio (0.46) than 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.17 |
ROIC/WACCN/A
WACC7.6%
2.3 Liquidity
A Current Ratio of 1.88 indicates that HCAT should not have too much problems paying its short term obligations.
The Current ratio of HCAT (1.88) is worse than 60.00% of its industry peers.
HCAT has a Quick Ratio of 1.88. This is a normal value and indicates that HCAT is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of HCAT (1.88) is worse than 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 |
3. Growth
3.1 Past
HCAT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.31%.
HCAT shows a small growth in Revenue. In the last year, the Revenue has grown by 4.64%.
Measured over the past years, HCAT shows a quite strong growth in Revenue. The Revenue has been growing by 14.63% on average per year.
EPS 1Y (TTM)-42.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)4.64%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%-0.04%
3.2 Future
The Earnings Per Share is expected to grow by 7.75% on average over the next years.
HCAT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.17% yearly.
EPS Next Y-25.32%
EPS Next 2Y14.66%
EPS Next 3Y21.21%
EPS Next 5Y7.75%
Revenue Next Year1.22%
Revenue Next 2Y-0.78%
Revenue Next 3Y0.39%
Revenue Next 5Y1.17%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 17.60 indicates a rather expensive valuation of HCAT.
HCAT's Price/Earnings ratio is rather cheap when compared to the industry. HCAT is cheaper than 91.43% of the companies in the same industry.
HCAT's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.34.
A Price/Forward Earnings ratio of 7.17 indicates a rather cheap valuation of HCAT.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HCAT indicates a rather cheap valuation: HCAT is cheaper than 97.14% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of HCAT to the average of the S&P500 Index (23.56), we can say HCAT is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.6 | ||
| Fwd PE | 7.17 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HCAT is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 106.97 |
4.3 Compensation for Growth
A more expensive valuation may be justified as HCAT's earnings are expected to grow with 21.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.66%
EPS Next 3Y21.21%
5. Dividend
5.1 Amount
No dividends for HCAT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.64
+0.04 (+1.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners79.37%
Inst Owner Change-1.01%
Ins Owners4.73%
Ins Owner Change9.13%
Market Cap186.73M
Revenue(TTM)316.06M
Net Income(TTM)-107.62M
Analysts73.33
Price Target4.02 (52.27%)
Short Float %8.95%
Short Ratio9.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.48%
Min EPS beat(2)-0.72%
Max EPS beat(2)15.68%
EPS beat(4)2
Avg EPS beat(4)89.55%
Min EPS beat(4)-46.95%
Max EPS beat(4)390.2%
EPS beat(8)5
Avg EPS beat(8)389.25%
EPS beat(12)9
Avg EPS beat(12)423.71%
EPS beat(16)13
Avg EPS beat(16)328.14%
Revenue beat(2)0
Avg Revenue beat(2)-1.62%
Min Revenue beat(2)-1.82%
Max Revenue beat(2)-1.41%
Revenue beat(4)0
Avg Revenue beat(4)-1.73%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)-1.41%
Revenue beat(8)1
Avg Revenue beat(8)-1.46%
Revenue beat(12)2
Avg Revenue beat(12)-1.03%
Revenue beat(16)5
Avg Revenue beat(16)-0.71%
PT rev (1m)-11.25%
PT rev (3m)-13.42%
EPS NQ rev (1m)-15.57%
EPS NQ rev (3m)-17.16%
EPS NY rev (1m)-6.82%
EPS NY rev (3m)-6.82%
Revenue NQ rev (1m)-2.55%
Revenue NQ rev (3m)-5.5%
Revenue NY rev (1m)-0.6%
Revenue NY rev (3m)-2.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.6 | ||
| Fwd PE | 7.17 | ||
| P/S | 0.59 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.56 | ||
| P/tB | N/A | ||
| EV/EBITDA | 106.97 |
EPS(TTM)0.15
EY5.68%
EPS(NY)0.37
Fwd EY13.94%
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS4.47
BVpS4.69
TBVpS-0.61
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.33% | ||
| ROE | -32.42% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.49% | ||
| FCFM | N/A |
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
F-Score5
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 83.43 | ||
| Cap/Depr | 43.42% | ||
| Cap/Sales | 6.58% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 | ||
| Altman-Z | -2.17 |
F-Score5
WACC7.6%
ROIC/WACCN/A
Cap/Depr(3y)36.51%
Cap/Depr(5y)42.93%
Cap/Sales(3y)5.5%
Cap/Sales(5y)5.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y-25.32%
EPS Next 2Y14.66%
EPS Next 3Y21.21%
EPS Next 5Y7.75%
Revenue 1Y (TTM)4.64%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%-0.04%
Revenue Next Year1.22%
Revenue Next 2Y-0.78%
Revenue Next 3Y0.39%
Revenue Next 5Y1.17%
EBIT growth 1Y28.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year162.38%
EBIT Next 3Y42.06%
EBIT Next 5Y29.55%
FCF growth 1Y24.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.97%
OCF growth 3YN/A
OCF growth 5YN/A
HEALTH CATALYST INC / HCAT FAQ
What is the fundamental rating for HCAT stock?
ChartMill assigns a fundamental rating of 2 / 10 to HCAT.
What is the valuation status for HCAT stock?
ChartMill assigns a valuation rating of 5 / 10 to HEALTH CATALYST INC (HCAT). This can be considered as Fairly Valued.
Can you provide the profitability details for HEALTH CATALYST INC?
HEALTH CATALYST INC (HCAT) has a profitability rating of 1 / 10.
Can you provide the financial health for HCAT stock?
The financial health rating of HEALTH CATALYST INC (HCAT) is 1 / 10.